Ces radiol. 2017, 71(4):260-264 | DOI: 10.55095/CesRadiol2017/036

Statement to the current situation with contrast agents for magnetic resonance imaging on the basis of gadolinium chelatesReview article

Josef Vymazal1, Petr Šustek2
1 Nemocnice Na Homolce, Praha
2 Právnická fakulta Univerzity Karlovy, Praha

The review article describes individual MR contrast agents on the basis of gadolinium chelates, it focuses on their physic-chemical properties and clinical use. The paper emphasizes schematic division of the contrast agents to linear and cyclic chelates because the situation in vivo is more complex. The paper focuses further on nephrogenic systemic fibrosis in relation to the use of several specific linear contrast agents. Regarding gadolinium retention in the brain the paper describes current level of knowledge where visible changes are present in the areas of high concentrations of metalloprotein ferritin. The same contrast agents related to nephrogenic systemic fibrosis also cause the most pronounced retention. However, even in this topic the situation is more complex. No convincing neurological symptomatology has been attributed with this retention and no histopathological changes were found in animal models after applications of significantly higher amounts of contrast agents. Finally, current legislative steps of regulation authorities in individual countries are described with the emphasis that these steps are inconsistent. Brief description of off-label use is described according to the current legislation.

Keywords: gadolinium, contrast agent, magnetic resonance, safety, systemic nephrogenic fibrosis, gadolinium retention

Accepted: November 15, 2017; Published: December 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vymazal J, Šustek P. Statement to the current situation with contrast agents for magnetic resonance imaging on the basis of gadolinium chelates. Ces radiol. 2017;71(4):260-264. doi: 10.55095/CesRadiol2017/036.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Caravan P, et al. Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. Chem Rev 1999; 99(9): 2293-2352. Go to original source... Go to PubMed...
    2. Vymazal J, et al. Frequency dependence of MR relaxation times. I. Paramagnetic ions. J Magn Reson Imaging 1993; 3(4): 637-640. Go to original source... Go to PubMed...
    3. Seidl Z, et al. Does higher gadolinium concentration play a role in the morphologic assessment of brain tumors? Results of a multicenter intraindividual crossover comparison of gadobutrol versus gadobenate dimeglumine (the MERIT Study). AJNR Am J Neuroradiol 2012; 33(6): 1050-1058. Go to original source... Go to PubMed...
    4. Rowley HA, et al. Contrast-enhanced MR imaging of brain lesions: a large-scale intraindividual crossover comparison of gadobenate dimeglumine versus gadodiamide. AJNR Am J Neuroradiol 2008; 29(9): 1684-1691. Go to original source... Go to PubMed...
    5. Maravilla KR. Gadobenate dimeglumine-enhanced MR imaging of patients with CNS diseases. Eur Radiol 2006; 16(Suppl 7): M8-15. Go to original source... Go to PubMed...
    6. Idee JM, et al. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update. Crit Rev Toxicol 2014; 44(10): 895-913. Go to original source... Go to PubMed...
    7. Kanal E. Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience. Magn Reson Imaging 2016; 34(10): 1341-1345. Go to original source... Go to PubMed...
    8. Elmholdt TR, et al. Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. NDT Plus 2010; 3(3): 285-287. Go to original source... Go to PubMed...
    9. Reilly RF. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008; 3(3): 747-751. Go to original source... Go to PubMed...
    10. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 2008; 66(2): 175-179. Go to original source... Go to PubMed...
    11. Gallivan JP, Dougherty DA. Cation-pi interactions in structural biology. Proc Natl Acad Sci USA 1999; 96(17): 9459-9464. Go to original source... Go to PubMed...
    12. Oksendal AN, Hals PA. Biodistribution and toxicity of MR imaging contrast media. J Magn Reson Imaging 1993; 3(1): 157-165. Go to original source... Go to PubMed...
    13. Kanda T, et al. High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 2014; 270(3): 834-841. Go to original source... Go to PubMed...
    14. Kanda T, et al. Gadolinium-based contrast agent accumulates in the brain even in subjects without severe renal dysfunction: evaluation of autopsy brain specimens with inductively coupled plasma mass spectroscopy. Radiology 2015; 276(1): 228-232. Go to original source... Go to PubMed...
    15. McDonald RJ, et al. Intracranial Gadolinium deposition after contrast-enhanced MR imaging. Radiology 2015; 275(3): 772-782. Go to original source... Go to PubMed...
    16. Quattrocchi CC, et al. Gadodiamide and Dentate Nucleus T1 hyperintensity in patients with meningioma evaluated by multiple follow-up contrast-enhanced magnetic resonance examinations with no systemic interval therapy. Invest Radiol 2015; 50(7): 470-472. Go to original source... Go to PubMed...
    17. Stojanov DA, et al. Increasing signal intensity within the dentate nucleus and globus pallidus on unenhanced T1W magnetic resonance images in patients with relapsing-remitting multiple sclerosis: correlation with cumulative dose of a macrocyclic gadolinium-based contrast agent, gadobutrol. Eur Radiol 2016; 26(3): 807-815. Go to original source... Go to PubMed...
    18. Weberling LD, et al. Increased signal intensity in the dentate nucleus on unenhanced T1-weighted images after Gadobenate Dimeglumine administration. Invest Radiol 2015; 50(11): 743-748. Go to original source... Go to PubMed...
    19. Kanda T, et al. Direct-acting Antiviral agents for the treatment of chronic hepatitis C virus infection. J Clin Transl Hepatol 2014; 2(1): 1-6. Go to original source... Go to PubMed...
    20. Vymazal J, Rulseh AMJ, Dracinsky M, Kotek J, Tarabek J, Majer P, Pingle M, Cigler P. Gadoliniium-ferritin complexes. Possible explanation of signal intensity changes in the deep brain nuclei after administration of MR contrast agents. MAGMA 2017. Proceedings of ESMRMB Meeting, in press.
    21. Lohrke J, et al. Histology and Gadolinium distribution in the rodent brain after the administration of cumulative high doses of linear and macrocyclic Gadolinium-based contrast agents. Invest Radiol 2017; 52(6): 324-333. Go to original source... Go to PubMed...
    22. Thomsen HS and R. European Society of Urogenital. ESUR guideline: gadolinium-based contrast media and nephrogenic systemic fibrosis. Eur Radiol 2007; 17(10): 2692-2696. Go to original source... Go to PubMed...
    23. Thomsen HS, Webb JAW, et al. Contrast media. Safety issues and ESUR guidelines. 3. vydání. Berlin, Heidelberg: Springer 2014; 25. Go to original source...
    24. European Commission, Stamp Commission Expert Group. Off-label use of medicinal products. 2017; 3.
    25. Věc T-452/14: Rozsudek Tribunálu ze dne 11. června 2015 - Laboratoires CTRS v. Komise, bod 79.
    26. Král J. Farmaceutické právo. 1. vydání. Praha: Erudium 2014: 116.

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content